Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Moderna in a note issued to investors ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme ...

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for Moderna in a research note issued to ...

Moderna Inc. (NYSE: MRNA) has revised its sales projections for 2025, lowering expectations due to sluggish demand for its ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...

The company now expects revenue for 2025 to fall between $1.5 billion and $2.5 billion, a steep reduction from its previous ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

A statewide grand jury didn’t find evidence that COVID-19 vaccine manufacturers broke federal or state laws when making and ...